Seagrass granule formulation for managing metabolic dysfunction-associated fatty liver disease, comprises bioactive formulation comprising phytoextracts from e.g. Halophila beccarii, Camellia sinensis, Linum usitatissimum, and Allium sativum, where granules are synthesized by wet granulation
	DEVI P U M; MATHAKALA V
	2024-12-14
专利权人	MATHAKALA V (MATH-Individual)
申请日期	2024-12-14
专利号	IN202441099008-A
成果简介	NOVELTY - A seagrass granule formulation comprises a bioactive formulation F1 comprising phytoextracts from 50 g Halophila beccarii, 25 g Camellia sinensis, 15 g Linum usitatissimum, 2.5 g Coccinia grandis, and 7.5 g Allium sativum, where the granules are synthesized using a wet granulation technique. USE - Seagrass granule formulation for managing metabolic dysfunction-associated fatty liver disease by improving glucose metabolism, enhancing insulin sensitivity, and reducing hepatic lipid accumulation, mitigating oxidative stress associated with MAFLD, improving liver function by reducing fat storage, reducing gastrointestinal side effects or dysphagia, and reducing inflammation. Test details are described but no results given. ADVANTAGE - The seagrass granule formulation has antioxidant (IC50 2,2-diphenyl-1-picrylhydrazyl (DPPH) of 66 µg/mL, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) of 52 µg/mL, nitric oxide scavenging 96 µg/mL, and advanced glycation end product (AGE) inhibition of 86 µg/mL), anti-diabetic activity (inhibiting α-amylase and α-glucosidase with IC50 values of 75 µg/mL and 77 µg/mL) and hepatoprotective (pancreatic lipase inhibition with IC50 value of 210 µg/mL) activities, excellent in vitro therapeutic properties, reduces hepatic lipid accumulation with serum triglyceride levels by 60% and low-density lipoprotein (LDL) cholesterol by 50%, and increases high-density lipoprotein (HDL) cholesterol by 60%, improved metabolic function, and improved antioxidant activity, and does not cause hepatotoxicity. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method for synthesizing seagrass granules, which comprises: (a) preparing a solution mixture containing 150 mg starch, 3 mg magnesium stearate, 250 mg dibasic calcium phosphate, 200 mg Pearlitol(RTM: Mannitol), 160 mg citric acid, 2 ml methylparaben and 0.5 ml propyl paraben along with 200 mg bioactive formulation F1; (b) uniformly mixing the prepared mixture in a high-shear mixer along with 2 ml methyl paraben as a preservative to ensure the effective incorporation of bioactive formulation into granule form; and (c) processing the mixture to form granules followed by drying and subsequent sieving to achieve desired size distribution and storing in airtight container to maintain its stability and efficacy for further use.
IPC 分类号	A23L-033/105 ; A61K-036/8962 ; A61P-001/16 ; A61P-003/10 ; A61P-039/06
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/14085
专题	中国科学院新疆生态与地理研究所
作者单位	MATHAKALA V (MATH-Individual)
推荐引用方式 GB/T 7714	DEVI P U M,MATHAKALA V. Seagrass granule formulation for managing metabolic dysfunction-associated fatty liver disease, comprises bioactive formulation comprising phytoextracts from e.g. Halophila beccarii, Camellia sinensis, Linum usitatissimum, and Allium sativum, where granules are synthesized by wet granulation. IN202441099008-A[P]. 2024.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。